Deoxyribonuclease I (Nickase)

An enzyme capable of hydrolyzing highly polymerized DNA by splitting phosphodiester linkages, preferentially adjacent to a pyrimidine nucleotide. This catalyzes endonucleolytic cleavage of DNA yielding 5'-phosphodi- and oligonucleotide end-products. The enzyme has a preference for double-stranded DNA.

Also Known As:

Networked: 1017 relevant articles (18 outcomes, 71 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yasuda, Toshihiro: 20 articles (04/2015 - 05/2004)
2.	Takeshita, Haruo: 13 articles (04/2015 - 01/2006)
3.	Kawai, Yasuyuki: 13 articles (08/2014 - 05/2004)
4.	Fujihara, Junko: 11 articles (04/2015 - 01/2006)
5.	Ueki, Misuzu: 10 articles (04/2015 - 07/2005)
6.	Kominato, Yoshihiko: 10 articles (01/2014 - 11/2005)
7.	Stamatoyannopoulos, John A: 9 articles (06/2015 - 03/2011)
8.	Iida, Reiko: 9 articles (04/2015 - 07/2006)
9.	Nakajima, Tamiko: 7 articles (01/2014 - 07/2006)
10.	Arakawa, Kenichiro: 6 articles (05/2012 - 05/2004)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2007 - "The use of DNAse I pre-treatment significantly increases the reliability and sensitivity of immunodetection of CKI nuclear factors, and should be useful for both developmental neurobiology studies as well as cancer diagnostic applications." 10/15/2015 - "Despite independent observations of such phenomena in diverse cancers for over 50 years, the potential for using DNase I as a clinical tool to prevent or treat cancer remains unexplored. " 02/01/2009 - "Incubation with DNase I inhibits tumor cell proliferation." 07/01/2004 - "Interestingly, degenerative 15-bp repeats found in the U3 region are differentially protected in DNase I footprint analysis by the walleye cell line nuclear extract and regressing-tumor nuclear extract. " 05/15/2002 - "Recent experiments indicate that oral VC:VK(3) increases the life-span of tumor-bearing nude mice and significantly reduces the growth rate of solid tumors without any significant toxicity by reactivating DNase I and II and inducing autoschizis. "
2.	Hypersensitivity (Allergy) 12/29/2000 - "By DNase I hypersensitivity mapping and deletion studies we have identified a 269-base pair activator element located 4.9 kilobases upstream from the transcription start site that acts as an enhancer. " 08/25/2000 - "To locate liver-specific elements in other segments of the human gene, DNase I hypersensitivity studies were performed with transcriptionally active, liver-derived HepG2 cells and with transcriptionally inactive HeLa cells. " 10/17/1996 - "DNase I hypersensitivity studies showed increased DNase I resistance and the loss of a hypersensitive site in differentiated F9 cells. " 05/13/1994 - "In order to localize the critical regulatory elements important for tissue-specific, high level WAP gene expression, DNase I hypersensitivity mapping studies of WAP transgenes were performed in nuclei isolated from mammary gland and liver. " 08/01/1993 - "We have chosen to use the approaches involving in situ nick translation and have shown that the patterns of DNase I hypersensitivity and of CpG islands on human chromosomes show a strict correspondence to R-banding patterns: Deviations from R-banding patterns reported by previous investigators who have made similar studies appear to be attributable to excessive digestion.(ABSTRACT TRUNCATED AT 250 WORDS)"
3.	Cystic Fibrosis (Mucoviscidosis) 04/01/2001 - "Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions." 11/01/2012 - "Moreover, as shown above, DNase I is utilized in the treatment of patients with cystic fibrosis. " 02/01/2004 - "The current status of deoxyribonuclease I in the management of cystic fibrosis was investigated and special attention given to the developments in delivery systems, such as dry powder inhalation. " 08/06/1996 - "Engineering actin-resistant human DNase I for treatment of cystic fibrosis." 07/17/1998 - "Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus."
4.	Pressure Ulcer (Bedsore) 01/01/1985 - "In a single-blind, randomized trial, the efficacy of topical streptokinase-streptodornase (Varidase) solution was compared with that of zinc oxide on necrotic pressure ulcers in 28 patients. " 07/01/1996 - "In a randomised, double-blind, controlled trial, a comparison was made of the relative efficacy of using streptokinase/streptodornase (Varidase) in a hydrogel (KY Jelly) or the hydrogel alone in the debridement of Grade IV pressure sores. "
5.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 08/01/2014 - "In the present study, we have extensively continued our previous investigations of the nonsynonymous single-nucleotide polymorphisms (SNPs) in the human DNase I (DNASE1) gene potentially relevant to systemic lupus erythematosus (SLE); therefore, all of the 58 nonsynonymous SNPs registered in the NCBI dbSNP database could be evaluated and it could be checked as to whether these SNPs might serve as a functional SNP. " 04/01/2007 - "Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility." 06/10/1973 - "[Studies on DNase I activity and its heat-labile inhibitor in systemic lupus erythematosus]." 02/10/1970 - "[Studies on Dnase I activity in systemic lupus erythematosus]." 08/01/2014 - "Identification of the functional alleles of the nonsynonymous single-nucleotide polymorphisms potentially implicated in systemic lupus erythematosus in the human deoxyribonuclease I gene."

Related Drugs and Biologics

1.	Streptokinase
2.	DNA (Deoxyribonucleic Acid)
3.	Streptodornase and Streptokinase
4.	Pancreatic Ribonuclease (Ribonuclease A)
5.	candidin
6.	Hydrogel
7.	Zinc Oxide
8.	K-Y jelly
9.	Immunoglobulin G (IgG)
10.	DNA-Directed RNA Polymerases (RNA Polymerase)

Related Therapies and Procedures

1.	Debridement
2.	Aftercare (After-Treatment)
3.	Enzyme Therapy
4.	Transplants (Transplant)
5.	Nutritional Support (Artificial Feeding)